Your browser doesn't support javascript.
loading
Identification of nucleobase chemical modifications that reduce the hepatotoxicity of gapmer antisense oligonucleotides.
Yoshida, Tokuyuki; Morihiro, Kunihiko; Naito, Yuki; Mikami, Atsushi; Kasahara, Yuuya; Inoue, Takao; Obika, Satoshi.
Afiliación
  • Yoshida T; Division of Molecular Target and Gene Therapy Products, National Institute of Health Sciences, Kawasaki, Kanagawa, Japan.
  • Morihiro K; Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan.
  • Naito Y; National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Ibaraki, Osaka, Japan.
  • Mikami A; Database Center for Life Science (DBCLS), 1111 Yata, Mishima, Shizuoka 411-8540, Japan.
  • Kasahara Y; National Institute of Genetics, 1111 Yata, Mishima, Shizuoka 411-8540, Japan.
  • Inoue T; Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan.
  • Obika S; Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan.
Nucleic Acids Res ; 50(13): 7224-7234, 2022 07 22.
Article en En | MEDLINE | ID: mdl-35801870
ABSTRACT
Currently, gapmer antisense oligonucleotide (ASO) therapeutics are under clinical development for the treatment of various diseases, including previously intractable human disorders; however, they have the potential to induce hepatotoxicity. Although several groups have reported the reduced hepatotoxicity of gapmer ASOs following chemical modifications of sugar residues or internucleotide linkages, only few studies have described nucleobase modifications to reduce hepatotoxicity. In this study, we introduced single or multiple combinations of 17 nucleobase derivatives, including four novel derivatives, into hepatotoxic locked nucleic acid gapmer ASOs and examined their effects on hepatotoxicity. The results demonstrated successful identification of chemical modifications that strongly reduced the hepatotoxicity of gapmer ASOs. This approach expands the ability to design gapmer ASOs with optimal therapeutic profiles.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Oligonucleótidos Antisentido / Enfermedad Hepática Inducida por Sustancias y Drogas Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Nucleic Acids Res Año: 2022 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Oligonucleótidos Antisentido / Enfermedad Hepática Inducida por Sustancias y Drogas Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Nucleic Acids Res Año: 2022 Tipo del documento: Article País de afiliación: Japón